EMEA Efforts To Be Innovation-Friendly Include Shorter Review Times
Executive Summary
The European Medicines Agency expects its push to promote innovation will lead to increases in marketing authorization applications in the coming years
You may also be interested in...
European Risk Management Guidelines Could Expedite Product Approval
The European Medicines Agency's new risk management guideline could help to shorten the drug delivery process, agency Executive Director Thomas Lonngren said during the Drug Information Association's EuroMeeting March 7 in Paris
EU Biosimilar Guidance Offers Window To Bypass Comparative Trials
Manufacturers seeking regulatory approval of a follow-on biologic in the EU may be able to forgo clinical comparability trials under certain conditions, according to final guidelines on similar biologics issued by the European Medicines Agency March 8
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011